vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Zepp Health Corp (ZEPP). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $10.5M, roughly 1.0× Zepp Health Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -2.1%, a 25.6% gap on every dollar of revenue. Over the past eight quarters, Zepp Health Corp's revenue compounded faster (-7.9% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Zepp Health Corp is a global digital health and smart wearable technology company. It develops and sells fitness trackers, smartwatches, and AI-powered health monitoring tools, serving individual consumers, sports teams, and healthcare providers across Asia, North America, and Europe, with core focus on wellness tracking and remote health management solutions.
ABUS vs ZEPP — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $10.5M |
| Net Profit | $2.5M | $-223.0K |
| Gross Margin | — | 38.2% |
| Operating Margin | 13.9% | -1.2% |
| Net Margin | 23.5% | -2.1% |
| Revenue YoY | 522.2% | — |
| Net Profit YoY | 112.7% | — |
| EPS (diluted) | $0.01 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $10.5M | ||
| Q2 25 | $10.7M | $8.2M | ||
| Q1 25 | — | $5.3M | ||
| Q3 24 | — | $5.9M | ||
| Q2 24 | — | $5.6M | ||
| Q1 24 | — | $5.5M | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | $11.4M |
| Q3 25 | — | $-223.0K | ||
| Q2 25 | $2.5M | $-1.1M | ||
| Q1 25 | — | $-2.7M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-2.0M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | $52.6K |
| Q3 25 | — | 38.2% | ||
| Q2 25 | — | 36.2% | ||
| Q1 25 | — | 37.3% | ||
| Q3 24 | — | 40.6% | ||
| Q2 24 | — | 40.3% | ||
| Q1 24 | — | 36.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 33.9% |
| Q3 25 | — | -1.2% | ||
| Q2 25 | 13.9% | -10.3% | ||
| Q1 25 | — | -47.7% | ||
| Q3 24 | — | -29.5% | ||
| Q2 24 | — | -24.3% | ||
| Q1 24 | — | -39.6% | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — |
| Q3 25 | — | -2.1% | ||
| Q2 25 | 23.5% | -13.0% | ||
| Q1 25 | — | -51.2% | ||
| Q3 24 | — | -31.2% | ||
| Q2 24 | — | -26.7% | ||
| Q1 24 | — | -36.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | 0.5% |
| Q3 25 | — | $-0.01 | ||
| Q2 25 | $0.01 | $-0.07 | ||
| Q1 25 | — | $-0.17 | ||
| Q3 24 | — | $-0.01 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.01 | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $8.7M |
| Total DebtLower is stronger | $0 | $9.6M |
| Stockholders' EquityBook value | $83.0M | $31.2M |
| Total Assets | $103.3M | $80.9M |
| Debt / EquityLower = less leverage | 0.00× | 0.31× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $8.7M | ||
| Q2 25 | $37.4M | $7.8M | ||
| Q1 25 | — | $10.7M | ||
| Q3 24 | — | $16.4M | ||
| Q2 24 | — | $17.0M | ||
| Q1 24 | — | $17.9M | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | $17.9M |
| Q3 25 | — | $9.6M | ||
| Q2 25 | $0 | $9.7M | ||
| Q1 25 | — | $9.6M | ||
| Q3 24 | — | $5.7M | ||
| Q2 24 | — | $7.3M | ||
| Q1 24 | — | $11.2M | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | $16.3M |
| Q3 25 | — | $31.2M | ||
| Q2 25 | $83.0M | $31.1M | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $44.6M | ||
| Q1 24 | — | — | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | $48.0M |
| Q3 25 | — | $80.9M | ||
| Q2 25 | $103.3M | $75.8M | ||
| Q1 25 | — | $71.6M | ||
| Q3 24 | — | $81.3M | ||
| Q2 24 | — | $79.7M | ||
| Q1 24 | — | $80.5M | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | $91.4M |
| Q3 25 | — | 0.31× | ||
| Q2 25 | 0.00× | 0.31× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | $-15.7M | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — |
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
